Akebia Therapeutics Announces Multiple Positive Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
January 14, 2025 11:06 AM ESTH.C. Wainwright analyst Ed Arce reiterated a Buy rating and $7.50 price target on Akebia Therapeutics (NASDAQ: AKBA)
The analyst comments "Affirm Buy and $7.50 PT. We employ a rNPV model to value AKBA shares. Our price target currently consists of: (1) $4.17... More



